Provera is used for treating certain menstrual problems or uterine problems (e.g., abnormal bleeding, endometrial hyperplasia).

Package	Price	Per Item	Savings	Order
90 pills x 2.5 mg	$51.51	Only $0.57 per pill	You Save $0.00
60 pills x 5 mg	$62.08	Only $1.03 per pill	You Save $0.00
90 pills x 5 mg	$71.55	Only $0.80 per pill	You Save $21.45

Clindamycin (rINN; unmixed /klɪndəˈmaɪsɨn/ ) is a lincosamide antibiotic. It is usually used to treat infections with anaerobic bacteria but can also be inured to to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne, and can be usable against some methicillin-resistant Staphylococcus aureus (MRSA) infections.

The most punitive common adverse effect of clindamycin is Clostridium difficile -associated diarrhea (the most attend regularly cause of pseudomembranous colitis). Although this side-effect occurs with about all antibiotics, including beta-lactam antibiotics, it is classically linked to clindamycin use.

Clindamycin is marketed underneath various trade names, including Dalacin , Clindacin , Cleocin , and Evoclin (clindamycin by itself), Duac , BenzaClin , and Arcanya (in coalition with benzoyl peroxide), and Ziana (with tretinoin). Clindamycin is also at one's disposal as a generic drug.

Indications

Clindamycin is used primarily to treat infections caused by susceptible anaerobic bacteria, including infections of the respiratory dissertation, skin and soft tissue infections, and peritonitis. In patients with hypersensitivity to penicillins, clindamycin may be utilized to treat infections caused by susceptible aerobic bacteria as well. It is also acclimated to to treat bone and joint infections, particularly those caused by Staphylococcus aureus . Timely application of clindamycin phosphate can be used to treat mild to moderate acne.

Bacterial

Conglomeration therapy in acne

Multiple studies have shown the use of clindamycin in conjunction with benzoyl peroxide, which is to hand both through prescription or over-the-counter, to be more effective in the treatment of acne than the use of either goods by itself. A single-blind study comparing this combination to adapalene, a retinoid, also inaugurate it to work faster and be significantly better tolerated than adapalene, as well as more stuff.

Clindamycin and adapalene in combination are also more effective than either upper alone, although adverse effects are more frequent; a single study rest pretreatment with adapalene (application of adapalene 3–5 minutes before clindamycin) to significantly enhancement the penetration of clindamycin into the skin, which may enhance efficacy.

Susceptible bacteria

It is most shit against infections involving the following types of organisms:

• Aerobic Gram-bullish cocci, including some members of the Staphylococcus and Streptococcus (e.g. pneumococcus) genera, but not enterococci.
• Anaerobic, Gram-pessimistic rod-shaped bacteria, including some Bacteroides , Fusobacterium , and Prevotella , although defiance is increasing in Bacteroides fragilis .

Most aerobic Gram-negative bacteria (such as Pseudomonas , Legionella , Haemophilus influenzae and Moraxella ) are unsubmissive to clindamycin, as are the facultative anaerobic Enterobacteriaceae. A notable exception is Capnocytophaga canimorsus , for which clindamycin is a gold medal-line drug of choice.

Other

It can also be useful in skin and soft series infections caused by methicillin-resistant Staphylococcus aureus (MRSA); many strains of MRSA are quietly susceptible to clindamycin.

Clindamycin is used in cases of suspected toxic shock syndrome, over in combination with a bactericidal agent such as vancomycin. The rationale for this nearly equal is a presumed synergy between vancomycin, which causes the death of the bacteria by itemization of the cell membrane, and clindamycin, which is a powerful inhibitor of toxin synthesis. Both in vitro and in vivo studies make shown that clindamycin reduces the production of exotoxins by staphylococci; it may also goad changes in the surface structure of bacteria that make them more delicate to immune system attack (opsonization and phagocytosis).

Clindamycin has been proven to diminution the risk of premature births in women diagnosed with bacterial vaginosis during cock's-crow pregnancy to about a third of the risk of untreated women.

Parasitic

Malaria

Assumed with chloroquine or quinine, clindamycin is effective and well-tolerated in treating Plasmodium falciparum malaria; the latter grouping is particularly useful for children, and is the treatment of choice for pregnant women who become infected in areas where partisans to chloroquine is common. Clindamycin should not be used as an antimalarial by itself, although it appears to be acutely effective as such, because of its slow action.

Other

The combination of clindamycin and quinine is the ideal treatment for severe babesiosis.

Clindamycin may also be used to treat toxoplasmosis, and, in aggregate with primaquine, is effective in treating mild to moderate Pneumocystis jirovecii pneumonia.

On tap forms

Clindamycin preparations for oral administration include capsules (containing clindamycin hydrochloride) and articulated suspensions (containing clindamycin palmitate hydrochloride). It is also available for topical management, in gel form and in a foam delivery system (both containing clindamycin phosphate), especially as a prescription acne treatment.

Several combination acne treatments containing clindamycin are also marketed, such as lone-product formulations of clindamycin with benzoyl peroxide—sold as BenzoClin (Sanofi-Aventis), Duac (a gel organization made by Stiefel), and Arcanya , among other trade names—and, in the United States, a composition of clindamycin and tretinoin, sold as Ziana . In India, vaginal suppositories containing clindamycin in party with clotrimazole are manufactured by Olive Health Care and sold as Clinsup-V . In Egypt, vaginal cream containing clindamycin produced by Biopharmgroup sold as "Vagiclind" indicated for vaginosis.

Clindamycin is elbow as a generic drug, for both systemic (oral and intravenous) and topical use.

Adverse effects

Common adverse drug reactions (ADRs) associated with clindamycin therapy—establish in over 1% of patients—include: diarrhea, pseudomembranous colitis, nausea, vomiting, abdominal travail or cramps, rash, and/or itch. High doses (both intravenous and oral) may root a metallic taste, and topical application may cause contact dermatitis.

Pseudomembranous colitis is a potentially-fatal condition commonly associated with clindamycin, but which also occurs with other antibiotics. Overgrowth of Clostridium difficile , which is inherently ungovernable to clindamycin, results in the production of a toxin that causes a range of adverse effects, from diarrhea to colitis and toxic megacolon.

Almost never—in less than 0.1% of patients—clindamycin therapy has been associated with anaphylaxis, blood dyscrasias, polyarthritis, jaundice, raised liver enzyme levels and/or hepatotoxicity.

Chemistry

Clindamycin is a semisynthetic second-hand of lincomycin, a natural antibiotic produced by the actinobacterium Streptomyces lincolnensis . It is obtained by 7( S )-chloro-swopping of the 7( R )-hydroxyl group of lincomycin.

Pharmacology

Pharmacokinetics

Approximately 90% of an oral measure of clindamycin is absorbed from the gastrointestinal tract and it is widely distributed throughout the heart, excluding the central nervous system. Adequate therapeutic concentrations can be achieved in bone. There is also on the go uptake into white blood cells, most importantly neutrophils.

Clindamycin is extensively metabolised in the liver, unquestionably by CYP3A4; some of its metabolites are active, such as N -dimethyl clindamycin and clindamycin sulfoxide. The elimination half-lifestyle is 1.5 to 5 hours. Clindamycin is primarily eliminated by hepatic metabolism; after an intravenous prescribe of clindamycin phosphate, about 4.5% of the dose is excreted in urine as clindamycin and respecting 0.35% as the phosphate salt. The metabolites are excreted primarily in the urine.

Mechanism of influence

Clindamycin has a bacteriostatic effect. It interferes with bacterial protein synthesis (in a like way to erythromycin, azithromycin and chloramphenicol), by binding preferentially to the 50S subunit of the bacterial ribosome.

The structures of the complexes between individual antibiotics (including clindamycin) and a Deinococcus radiodurans ribosome have been solved by X-ray crystallography by a cooperate from the Max Planck Working Groups for Structural Molecular Biology, and published in the fortnightly Nature .

Interactions

Clindamycin may prolong the effects of neuromuscular-blocking drugs. Its similarity to the means of action of macrolides and chloramphenicol means they should not be given simultaneously, as this causes strife and possible cross-resistance.

Veterinary use

The veterinary uses of clindamycin are quite alike resemble to its human indications, and include treatment of osteomyelitis, skin infections, and toxoplasmosis, for which it is the hypnotic of choice in dogs and cats. Toxoplasmosis rarely causes symptoms in cats, but can do so in bloody young or immunocompromised kittens and cats. Toxoplasmosis is contagious to humans, and therefore cat owners, in particular pregnant women, should take precautions to prevent the spread of the disease.

See also

• Protein combining inhibitor

References

1. ^ ^{a b} Daum RS (2007). "Clinical practice. Skin and soft-chain infections caused by methicillin-resistant Staphylococcus aureus". N Engl J Med 357 (4): 380–90. doi: 10.1056/NEJMcp070747 . PMID 17652653.  
2. ^ ^{a b} Thomas C, Stevenson M, Riley TV (2003). "Antibiotics and dispensary-acquired Clostridium difficile-associated diarrhoea: a systematic review". J Antimicrob Chemother 51 (6): 1339–50. doi: 10.1093/jac/dkg254 . PMID 12746372.   Generous full text
3. ^ ^{a b} "Cleocin I.V. Indications & Dosage". RxList.com. 2007 . http://www.rxlist.com/cgi/generic/clindamyciniv_ids.htm . Retrieved on 2007-12-01 .  
4. ^ Darley ES, MacGowan AP (2004). "Antibiotic treatment of gram-complete bone and joint infections". J Antimicrob Chemother 53 (6): 928–35. doi: 10.1093/jac/dkh191 . PMID 15117932.   Free full quotation
5. ^ Feldman S, Careccia RE, Barham KL, Hancox J (2004). "Diagnosis and treatment of acne". Am Fam Physician 69 (9): 2123–30. PMID 15152959.   Unoccupied full text
6. ^ Cunliffe WJ, Holland KT, Bojar R, Levy SF (2002). "A randomized, doppelgaenger-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with regard to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris". Clin Ther 24 (7): 1117–33. doi: 10.1016/S0149-2918(02)80023-6 . PMID 12182256.  
7. ^ Leyden JJ, Berger RS, Dunlap FE, Ellis CN, Connolly MA, Levy SF (2001). "Balance of the efficacy and safety of a combination topical gel formulation of benzoyl peroxide and clindamycin with benzoyl peroxide, clindamycin and means gel in the treatments of acne vulgaris". Am J Clin Dermatol 2 (1): 33–9. doi: 10.2165/00128071-200102010-00006 . PMID 11702619.  
8. ^ Lookingbill DP, Chalker DK, Lindholm JS, et al (1997). "Treatment of acne with a league clindamycin/benzoyl peroxide gel compared with clindamycin gel, benzoyl peroxide gel and channel gel: combined results of two double-blind investigations". J Am Acad Dermatol 37 (4): 590–5. doi: 10.1016/S0190-9622(97)70177-4 . PMID 9344199.  
9. ^ Langner A, Chu A, Goulden V, Ambroziak M (2008). "A randomized, only-blind comparison of topical clindamycin + benzoyl peroxide and adapalene in the treatment of calm to moderate facial acne vulgaris". Br J Dermatol 158 (1): 122–9. PMID 18047518.  
10. ^ Wolf JE, Kaplan D, Kraus SJ, et al (2003). "Efficacy and tolerability of combined contemporary treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded swotting". J Am Acad Dermatol 49 (3 Suppl): S211–7. doi: 10.1067/S0190-9622(03)01152-6 . PMID 12963897.  
11. ^ Jain GK, Ahmed FJ (2007). "Adapalene pretreatment increases follicular shrewdness of clindamycin: in vitro and in vivo studies". Indian J Dermatol Venereol Leprol 73 (5): 326–9. PMID 17921613.   For nothing full text
12. ^ ^{a b c d} "Lincosamides, Oxazolidinones, and Streptogramins". Merck Manual of Diagnosis and Psychoanalysis . Merck & Co., Inc.. November 2005 . http://www.merck.com/mmpe/print/sec14/ch170/ch170g.html . Retrieved on 2007-12-01 .  
13. ^ ^{a b} Bell EA (January 2005). "Clindamycin: new look at an old panacea". Infectious Diseases in Children . http://www.idinchildren.com/200501/pharmconsult.asp . Retrieved on 2007-12-01 .  
14. ^ Gold, Howard S.; Robert C. Moellering, Jr. (1999). "Macrolides and clindamycin". in Tap root, Richard E.; Francis Waldvogel, Lawrence Corey, Walter E. Stamm. Clinical catching diseases: a practical approach . Oxford: Oxford University Cluster. pp. 291–7. ISBN 0-19-508103-X.   Retrieved on January 19, 2009 through Google Publication Search.
15. ^ Jolivet-Gougeon A, Sixou JL, Tamanai-Shacoori Z, Bonnaure-Mallet M (April 2007). "Antimicrobial treatment of Capnocytophaga infections". Int J Antimicrob Agents 29 (4): 367–73. doi: 10.1016/j.ijantimicag.2006.10.005 . PMID 17250994.  
16. ^ Annane D, Clair B, Salomon J (2004). "Managing toxic nervous exhaustion syndrome with antibiotics". Expert Opin Pharmacother 5 (8): 1701–10. doi: 10.1517/14656566.5.8.1701 . PMID 15264985.  
17. ^ Coyle EA, Association of Infectious Diseases Pharmacists (2003). "Targeting bacterial virulence: the r of protein synthesis inhibitors in severe infections. Insights from the Society of Catching Diseases Pharmacists". Pharmacotherapy 23 (5): 638–42. doi: 10.1592/phco.23.5.638.32191 . PMID 12741438.   Free full text with registration at Medscape
18. ^ Gemmell CG, O'Dowd A (1983). "Normal of protein A biosynthesis in Staphylococcus aureus by certain antibiotics: its effect on phagocytosis by leukocytes". J Antimicrob Chemother 12 (6): 587–97. doi: 10.1093/jac/12.6.587 . PMID 6662837.  
19. ^ Gemmell CG, Peterson PK, Schmeling D, et al (1981). "Potentiation of opsonization and phagocytosis of Streptococcus pyogenes following advance in the presence of clindamycin". J Clin Invest 67 (5): 1249–56. PMID 7014632.   Full text at PMC: 370690.
20. ^ Lamont RF (2005). "Can antibiotics frustrate preterm birth—the pro and con debate". BJOG 112 Suppl 1 : 67–73. doi: 10.1111/j.1471-0528.2005.00589.x . PMID 15715599.  
21. ^ ^{a b} Lell B, Kremsner PG (2002). "Clindamycin as an antimalarial dose: review of clinical trials". Antimicrob Agents Chemother 46 (8): 2315–20. doi: 10.1128/AAC.46.8.2315-2320.2002 . PMID 12121898.   Honest full text
22. ^ ^{a b} Griffith KS, Lewis LS, Mali S, Parise ME (2007). "Treatment of malaria in the Cooperative States: a systematic review". JAMA 297 (20): 2264–77. doi: 10.1001/jama.297.20.2264 . PMID 17519416.   Free ample text
23. ^ Homer MJ, Aguilar-Delfin I, Telford SR, Krause PJ, Persing DH (2000). "Babesiosis". Clin Microbiol Rev 13 (3): 451–69. doi: 10.1128/CMR.13.3.451-469.2000 . PMID 10885987.   Extra full text
24. ^ Pleyer U, Torun N, Liesenfeld O (2007). "" (in German). Ophthalmologe 104 (7): 603–15, grill 616. doi: 10.1007/s00347-007-1535-8 . PMID 17530262. w writes: "w"

2 writes: "2"

1 writes: "1"

h writes: "h"

S writes: "S"

e writes: "e"

R writes: "R"

h writes: "h"

3 writes: "3"

0 writes: "0"

I writes: "I"

2 writes: "2"

h writes: "h"

1 writes: "1"

1 writes: "1"